Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06331130
Recruiting Observational

Mesenteric Infiltration in Ovarian Cancer

NCT06331130 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Observational
Started
2024-03-01
Last updated
2025-03-12

Condition(s) studied

Ovary Cancer

Investigational drug(s) / intervention(s)

Computed Tomography

Computed Tomography: Computed Tomography done according to Clinical Practice to assess mesenteric involvment

Study summary

To evaluate if CT features at diagnosis in patients with HGSOC can be used to build an Artificial Intelligence model capable of discerning the pathological involvement of the mesentery, assessing the potential impediments for an optimal debulking surgery and predicting the development of resistance to platinum based chemotherapeutic agents.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Women with confirmed HGSOC wiht mesenteric involvment 2. Age \> 18 years 3. FIGO STAGE IIIB-IV 4. Primary diagnosis 5. Signed informed consent Exclusion Criteria: 1. Non-serous high grade epithelial ovarian cancer (serous low grade, mucinous, clear cell carcinoma, endometrioid or non-epithelial ovarian cancer) 2. Early stage disease (I and II stage) 3. CT scan not available 4. Non-primary diagnosis or patient subjected to neoadjuvant chemotherapy

Primary outcome measure(s)

  • Preoperative Artificial Intelligence assisted CT-based evaluation — 1 year
    Preoperative Artificial Intelligence assisted CT-based prediction of patients with suboptimal debulking at surgery due to diffuse mesenteric disease or mesenteric retraction.

Trial sites (1)

FacilityCityRegionStatus
Advanced Radiology Center Roma Italy Recruiting

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy

Spatial Radiogenomics of Ovarian Cancer Recruiting
Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies Recruiting
Echocardiographic Characterization of Cardiac Amyloidosis Recruiting
ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study Active, not recruiting
Youth Suicide Risk Factors, Reduction of Suicide Risk Factor in Youth People Recruiting

Other trials for the same condition

No-Stoma Policy in Advanced Ovarian Cancer Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06331130 on ClinicalTrials.gov ↗ ← All trials in Italy